2026年的春天，对于中国创新药行业而言，是一个检验“成色”的季节。 3月29日，翰森制药（03692.HK）发布了2025年全年业绩报告。在医药行业经历资本寒冬洗礼、市场从“炒作估值”转向“验证现金流”的当下，这份财报不仅关乎一家企业，更被视为观察中国创新药头部企业能否穿越周期的窗口。 财报显示，报告期内翰森制药实现总收入约150.28亿元，同比增长22.6%；溢利约55.55亿元，同比增长...
Source Link2026年的春天，对于中国创新药行业而言，是一个检验“成色”的季节。 3月29日，翰森制药（03692.HK）发布了2025年全年业绩报告。在医药行业经历资本寒冬洗礼、市场从“炒作估值”转向“验证现金流”的当下，这份财报不仅关乎一家企业，更被视为观察中国创新药头部企业能否穿越周期的窗口。 财报显示，报告期内翰森制药实现总收入约150.28亿元，同比增长22.6%；溢利约55.55亿元，同比增长...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.